Autres langues NextCure, Inc.

Actions

NXTC

US65343E1082

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,35 ^USD	+4,65 %		-15,62 %	+18,42 %

08/04	NextCure, Inc. et LigaChem Biosciences, Inc. présentent des données précliniques sur le conjugué anticorps-médicament B7-H4 à l'AACR 2024	CI
04/04	NextCure, Inc. nomme Rakesh Dixit au conseil consultatif scientifique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024	24/04
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024	08/04
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board	04/04
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board	04/04
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference	02/04
NextCure : March 2024 Corporate Presentation	21/03
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
NextCure Provides Business Update and Reports Full Year 2023 Financial Results	21/03
North American Morning Briefing : Markets on Hold -2-	20/03
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05/03
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05/03
Top Premarket Decliners	27/02
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18/01
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18/01
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
NextCure Provides Year-End Clinical Pipeline Updates	14/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NextCure, Inc.

Actions

NXTC

US65343E1082

Autres langues

Filtres